Last reviewed · How we verify
Pradax
At a glance
| Generic name | Pradax |
|---|---|
| Also known as | Pradax dabigatran etexilate |
| Sponsor | Ross Leighton |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days (PHASE4)
- Dabigatran Following Transient Ischemic Attack and Minor Stroke (PHASE2)
- DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation (PHASE4)
- Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke (PHASE2)
- An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pradax CI brief — competitive landscape report
- Pradax updates RSS · CI watch RSS
- Ross Leighton portfolio CI